

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

# NOTICE OF ALLOWANCE AND FEE(S) DUE

7590

03/19/2007

Julie Anne Knight Aventis Pharmaceuticals, Inc. Patent Department Route #202-206/ P.O. Box 6800 Bridgewater, NJ 08807-0800

EXA	AMINER		
RAO,	DEEPAK R		
ART UNIT	PAPER NUMBER		

DATE MAILED: 03/19/2007

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/642 970	08/18/2003	Olaf Ritzeler	DEA V2002/0063 US NP	3385

TITLE OF INVENTION: INDOLE DERIVATIVES OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IKB KINASE

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1400	\$300	\$0	\$1700	06/19/2007

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

#### HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

### PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450 or Fax (571)-273-2885

in m

appropriate All further	correspondence includir ed below or directed oth	ng the Patent advance of	rders and notification	of m	naintenance fees w	rill be :	mailed to the current	correspondence address as rate "FEE ADDRESS" for
CURRENT CORRESPOND	ENCE ADDRESS (Note: Use BI	ock 1 for any change of address)		Fee(	s) Transmittal. Thi	s certif l paper	icate cannot be used for	domestic mailings of the or any other accompanying at or formal drawing, must
Julie Anne Kn Aventis Pharma Patent Departme	ight ceuticals, Inc.	//2007		I her	Cert eby certify that the	tificate	of Mailing or Transr	nission deposited with the United t class mail in an envelope above, or being facsimile tte indicated below.
Route #202-206 Bridgewater, NJ	/ P.O. Box 6800 1 08807-0800		•					(Depositor's name)
Dilago water, 1 to								(Signature)
				L				(Date)
APPLICATION NO.	FILING DATE		FIRST NAMED INVEN	TOR		ATTO	RNEY DOCKET NO.	CONFIRMATION NO.
10/642,970	08/18/2003	EC OD DENZIMIDA 20	Olaf Ritzeler	:OD I	MODI II ATING II		V2002/0063 US NP	3385
TITLE OF INVENTION	: INDOLE DERIVATIV	ES OR BENZIMIDAZO	DLE DERIVATIVES F	OK i	WODULATING IF	VD KII	NASE	
					,			
APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE D	UE	PREV. PAID ISSUI	E FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1400	\$300		. \$0		\$1700	06/19/2007
EXAM	INER	ART UNIT	CLASS-SUBCLASS	3				
RAO, DE	EEPAK R	1624	514-275000		,			
CFR 1.363).  Change of corresp Address form PTO/S  "Fee Address" ind	ence address or indicatio condence address (or Cha B/122) attached. dication (or "Fee Address oz or more recent) attach	inge of Correspondence	2. For printing on (1) the names of u or agents OR, alter (2) the name of a registered attorney 2 registered patent listed, no name will	ip to mativ single or a	ely, e firm (having as a gent) and the nam- meys or agents. If	t attorn	era 2 p to	
PLEASE NOTE: Un recordation as set for (A) NAME OF ASSI	less an assignee is ident th in 37 CFR 3.11. Comp GNEE		data will appear on to the control of the control o	he pag an a	atent. If an assignassignment.	OUNT	TRY)	ocument has been filed for
Please check the appropr	riate assignee category or	categories (will not be pr	rinted on the patent) :		Individual L Co	rporati	on or other private gro	up entity  Government
	are submitted: No small entity discount p # of Copies	permitted)	☐ A check is enclos☐ Payment by credi☐ The Director is he	sed. it care	d. Form PTO-2038	is atta	required fee(s), any det	
	s SMALL ENTITY statt	us. See 37 CFR 1.27.	• •		,		FITY status. See 37 CF	
NOTE: The Issue Fee an interest as shown by the	d Publication Fee (if req records of the United Sta	uired) will not be accepte tes Patent and Trademark	ed from anyone other the Office.	han tl	he applicant; a regi	stered a	attorney or agent; or th	e assignee or other party in
Authorized Signature					Date			•
Typed or printed nam	ne				Registration N	Io		
This collection of inform an application. Confiden submitting the complete this form and/or suggest Box 1450, Alexandria, V Alexandria, Virginia 223	tiality is governed by 35 d application form to the ions for reducing this bu /irginia 22313-1450. DC	FR 1.311. The informatic U.S.C. 122 and 37 CFR USPTO. Time will vary rden, should be sent to the ONOT SEND FEES OR	on is required to obtain 1.14. This collection is depending upon the le Chief Information COMPLETED FORM	or reis esti indiv Office IS TO	ctain a benefit by the imated to take 12 reidual case. Any corr, U.S. Patent and DTHIS ADDRESS	he publ ninutes mment Traden S. SENI	ic which is to file (and to complete, includin s on the amount of tin ark Office, U.S. Depa D TO: Commissioner f	by the USPTO to process) g gathering, preparing, and ne you require to complete rument of Commerce, P.O. or Patents, P.O. Box 1450,

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/642,970	08/18/2003	Olaf Ritzeler	DEA V2002/0063 US NP 3385		
75	90 03/19/2007		EXAM	INER	
Julie Anne Knigh	t		RAO, DE	EPAK R	
Aventis Pharmaceuticals, Inc.			ART UNIT	PAPER NUMBER	
Patent Department Route #202-206/ P	O. Box 6800		1624 DATE MAILED: 03/19/200'	7	

# Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 111 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 111 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.